An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (Under Process) , 

 ISSN 2394-3211

Impact Factor: 4.897

 ICV - 79.57



Bop. M. C., Sow P. G.* and Ndiaye P.


Background: Viral hepatitis constitutes a major public health problem world wide. The consequences of chronic liver diseases put a considerable economic burden upon the communities afflicted with the diseases. Viral hepatitis is the predominant risk factor associated with hepatocellular carcinoma. Objective: The aim of the present research is to carry out epidemiological studies concerning the laboratory out-come management of Hepatitis C co – infection with HIV and TB in a well defined hospital based population. Materials and Methods: Epidemiological studies were carried out among 1320 patients admitted at Bio-Amarie Laboratory of biology/Kaolack come management of hepatitis C (HCV) and Co – infections with HIV and TB over a period of four years (2012 – 2016). The grand diagnostic kits were used to analyze blood samples for HBV, HCV and HIV while sputum samples were analyzed for TB using the Zel Nielsen (ZN) staining technique. Results: A CD4 lymphocyte count of 0-200 cells/mml was found in 625 (47.3%) individuals. Out of these, 393 were found to be in WHO stage l clinical status. A further 409 with CD4 count of 201-400 cell/mml were grouped as stage lll (254) and stage IV (155).These together was determined as being eligible for anti-viral therapy. Of those eligible for anti-viral 52 and 80 were infected with HCV and HIV respectively. With respect to subjects management outcome in the hepatitis C infected subjects, follow-up was lost in 44(71.0%) while 11(17.7%) subjects survived and 7 (11. 3%) died. Similarly, subjects managements out-come amongst HIV and TB co-infected with HCV infections were fallow-up was lost in 34 (77.3%), 7 (15.9%) survived and 3 (6.8%) died. With respect to TB smear positive co-infected with HCV, subjects management out-come in 17 (58.6%) fallow-up was lost, 6 (20.6%) survived while 6 (20.6%) died. Conclusion: In respect to CD4 lymphocyte count and WHO clinical staging subjects were selected for Antiviral therapy management out-come showed that there was loss of fallow-up for majority of the subjects. However, in those that were successfully monitored, survival rate was consistently higher than mortality rate for all categories of patients except for cases of co-infections by HCV/TB where survival and mortality rates was equal.

Keywords: .

[Full Text Article]



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 February 2019 Issue has been Published, Kindly check it on


    FEBRUARY 2019 Issue has been successfully launched on 1 February 2019

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from 4.161 to 4.897 due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (Under Process)